Systemic Treatments in favorable and very favorable risk metastatic #RenalCellCarcinoma: Real-world evidence from the International @mRCC Database Consortium. Presented by @ZarbaMartin1. #ASCO24 written coverage by @RKSayyid > https://t.co/1FVjj3jT6y @ASCO
⭐️ RAPID ORALS RENAL ⭐️
“Systemic treatments in favorable and very favorable risk metastatic renal cell carcinoma (mRCC): Real world evidence from the International mRCC Database Consortium (IMDC).”
Dr Martin Zarba @DrDanielHeng
IMDC FAV (n = 611)
✅ Nivo/Ipi: ORR (35%), 2yr OS 86.4%
✅ IO/TKI: ORR (51.4%), 2yr OS 84.1%
✅ TKI: ORR (37.9%), 2yr OS 81.1%
IMDC VERY FAV (n= 165)
(Dx to systemic therapy ≥3yr,
KPS > 90, and no brain, liver, or bone metastasis)
✅ Nivo/Ipi: ORR (23.5%), 2yr OS 71.3%
✅ IO/TKI: ORR (58.1%), 2yr OS 87.2%
✅ TKI: ORR (55%), 2yr OS 92.1%
The debate for treatment of IMDC good risk continues #ASCO24 . The data presented supports the ESMO weak recommendations for ipi/nivo in the good risk population, but it doesn’t look so good in the rare very good risk group - while this could be noise it could also be biology.
Great presentation by @ZarbaMartin1 at #ASCO24
A subgroup analysis of #IMDC of favorable and very favorable risk patients.
Still a #VEGF inhibitors are the pillar of treatment for this subgroup.
The IMDC story continues with a new very favourable group (good risk with no visceral mets and 3yrs since surgery).All the pts did well but Ipi/nivo was least impressive. Modest numbers & patient selection confounding, but there are VEGF mono sensitive slow growing tumors #ASCO24